跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 7,636 条关于
“KRAS G12D NSCLC”
全部
7,636
临床试验
5,636
药物
268
机构
4
资讯
1,728
6个月前
JingFang Medicine's GFH375 Receives China's First Breakthrough Therapy Designation for KRAS G12D-Mutated NSCLC
上个月
GenFleet's Oral KRAS G12D Inhibitor GFH375 Enters Registrational Phase III Trial in NSCLC, First of Its Kind Globally
8个月前
Verastem Discontinues KRAS G12C Trial to Focus on Promising G12D Inhibitor with 69% Response Rate
前天
GenFleet's Oral KRAS G12D Inhibitor GFH375 Posts Strong Phase II Results in Pretreated NSCLC, Paving Way for First Global Phase III
11个月前
HengRui Advances KRAS G12D Inhibitor HRS-4642 to Phase 3 Trial in Pancreatic Cancer
2年前
AstraZeneca Secures KRAS G12D Inhibitor in $419M Deal with Usynova
去年
Revolution Medicines Reports Promising Results for Zoldonrasib in KRAS G12D Mutant Lung Cancer
上个月
KRAS G12C: From 'Undruggable' to Druggable with Sotorasib and Adagrasib
去年
Daraxonrasib and Zoldonrasib Show Promise in RAS-Mutated Pancreatic Cancer
11个月前
First-in-Human Trial Shows Engineered Exosomes Safely Target KRAS G12D in Pancreatic Cancer
第 1 页,共 173 页
上一页
下一页